ACHV — Achieve Life Sciences, Inc.
Is ACHV overbought or oversold? Here is the current MarketMoodz read.
Achieve Life Sciences, Inc. (ACHV) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $6.32. The rating moved from Oversold to Strong Oversold on November 13, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$6.32
- Last changeMoved from Oversold to Strong Oversold on November 13, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Achieve Life Sciences, Inc. (ACHV) is a clinical-stage specialty biotech focused on smoking cessation with a small-cap profile that makes the equity highly event-driven. The company’s primary value drivers are clinical readouts, regulatory progress, and potential partnering or licensing agreements; success on any of these fronts could produce material upside given the large addressable market and active M&A interest in attractive assets. Offsetting this upside are typical small-biotech constraints: limited near-term cash, the probability of further financing and dilution, regulatory hurdles, and strong incumbent competition. Sector dynamics show investor preference for larger, defensive pharma names and some financing pressure in mid/small-cap biotech, which could weigh on the stock in the absence of positive company-specific news.
Key factors
- Clinical-stage asset in a large addressable market (smoking cessation) with potential for meaningful revenue if approved/licensed
- Clear near- to mid-term binary catalysts: clinical data readouts, regulatory interactions, or commercial/partnering announcements that could re-rate the stock
- Niche differentiation versus nicotine replacement and existing prescription therapies could facilitate adoption if efficacy/safety profile is compelling
- Sector flows into healthcare and selective biopharma M&A appetite among large pharma create a constructive backdrop for partnership or acquisition interest
- Relatively small market cap profile allows for sharp upside on positive news given low liquidity/float
Risks
- Clinical trial failure or data that is weaker than market expectations, which would likely trigger a sharp share-price decline
- Limited cash runway and the likelihood of additional financing that would dilute existing shareholders
- Regulatory risk: FDA/other agency rejection, lengthy review or additional trial requirements
- Competitive pressures from established therapies (e.g., varenicline) and nonpharmacologic alternatives (vaping, NRT, behavioral programs)
- Sector-wide financing dynamics (convertible-debt issuance, hedging pressure) that can depress mid/small-cap biotech valuations independent of fundamentals
- Low visibility in social and institutional sentiment (no clear social/research signals available), increasing event-driven volatility
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for ACHV — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.